NEW YORK (GenomeWeb News) – Celera said today that it has licensed the rights to use Medical Therapies Limited's patent portfolio for the protein midkine in its lung cancer diagnostics programs.

Under the exclusive license with Sydney-based Medical Therapies, Celera will pay up front and milestone payments and royalties on product sales over the life of the patents. Specific financial details were not disclosed by the firms.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The Jackson Laboratory has filed a complaint accusing Nanjing University of breeding and re-selling its mouse models, the Hartford Courant reports.

Oxford researchers are turning to virtual reality to visualize genes and regulatory elements, Phys.org says.

In Science this week: neutrophils rely on microRNA to protect against lung inflammation, and more.

China is moving forward with plans to sequence a million citizens, the Wall Street Journal reports.